https://www.selleckchem.com/pr....oducts/4-hydroxytamo
Actuarial rates of new endocrinopathy were 17% at 2 yr (95% CI 10%-25%) and 31% at 5 yr (95% CI 20%-42%). On univariate analysis, sex (P=.02), gland volume (P=.03), mean gland dose (P.0001), and BED significantly predicted new hypopituitarism (P.0001). After adjusting for sex and gland volume, BED45 Gy2.47 and mean gland dose10Gy were significantly associated increased risk of hypopituitarism (hazard ratio [HR]=14.32, 95% CI=4.26-89.0, P.0001; HR=11.91, 95% CI=3.54-74.0, P.0001). BED p
Like
Comment
Share
